Navigation Links
Interim Results Presented at EASL from PROVE 1 Clinical Trial of,Investigational Drug Telaprevir in Patients with Genotype 1,Hepatitis C

on PROVE 2 data, regimens that may exclude RBV. Vertex expects to focus on treatment durations of no more than 24 weeks. Vertex and Tibotec are planning to meet with regulatory authorities to discuss the Phase 3 design in mid-2007 and are planning to initiate Phase 3 clinical development in the fourth quarter of 2007. The registration strategy and timing of an NDA filing will be dependent on discussions with regulatory authorities.

PROVE 1 Results at EASL

Interim 12-week antiviral analysis of PROVE 1

A total of 250 patients were enrolled in PROVE 1 and received at least one dose of telaprevir or placebo in addition to Peg-interferon alfa-2a (peg-IFN) + ribavirin (RBV) in the study. A total of 175 patients received at least one dose of telaprevir in 1 of 3 arms (treatment arms B, C and D) and 75 patients received at least one dose of placebo (arm A). Treatment with telaprevir resulted in a high proportion of patients achieving a rapid viral response at 4 weeks. At the time of the interim analysis, all patients had either completed 12 weeks or discontinued from the study prior to week 12. Available 4-week and 12-week results are detailed in the following table: -0-

 Interim HCV RNA results for Patients Enrolled in the PROVE 1 Trial

---------------------------------------------------------------------

Treatment Assignment            Patients Patients Patients Patients

                                 with     with     with     with HCV

                                 HCV RNA  HCV RNA  HCV RNA  RNA (less

                                 (less    (less    (less    than)10

                                 than)30  than)10  than)10  IU/mL at

                                 IU/mL    IU/mL    IU/mL    end of 12

                                 at end   at end   at end   weeks of

                                 of 4     of 4     of 12    dosing

                                 weeks    weeks    weeks    (last on-

                 
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
(Date:8/3/2015)... ROSEMONT, Ill. , Aug. 3, 2015 ... ankle problem, and you,re looking for the best possible ... for the best outcome too, and now there,s a ... there. Following steps recommended by the American Orthopaedic ... after surgery can help you avoid complications and heal ...
(Date:8/3/2015)... 3, 2015 ReportsnReports.com adds ... with 2020 forecasts as well as Global Medical ... devices intelligence collection of its library. ... 2020 forecasts spread across 164 pages, talking about ... and figures is now available at http://www.reportsnreports.com/reports/407046-global-medical-simulation-industry-report-2015.html ...
(Date:8/3/2015)... BUFFALO, N.Y. , Aug. 3, 2015 /PRNewswire/ ... the Wilmot Cancer Institute to the OmniSeq SM ... from Roswell Park Cancer Institute (RPCI) and announced ... products that support a physician-driven, collaborative approach to ... patient outcomes.  Wilmot Cancer Institute is a rapidly ...
Breaking Medicine Technology:Patient Guide: How to Prepare for Surgery 2Medical Simulation Market to see 14% CAGR to 2019 2Medical Simulation Market to see 14% CAGR to 2019 3Medical Simulation Market to see 14% CAGR to 2019 4Medical Simulation Market to see 14% CAGR to 2019 5Medical Simulation Market to see 14% CAGR to 2019 6OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3
... SAN DIEGO, April 27, 2012 The Centers for ... has quadrupled in a decade to nearly 15,000 in ... South Carolina, the number of people misusing or abusing ... and underscoring the need for access to quality care ...
... /PRNewswire-iReach/ -- SolutionStart, Corp., a leading provider of ... to announce John Karagiannis as its new Vice President ... over 12-years of strong experience in Information Technology having ... Designer, and Analyst providing comprehensive technical and business support ...
Cached Medicine Technology:Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 2Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 3Millennium Laboratories Sponsors Educational Programs in Support of Safe Prescribing Practices at Regional Pain Society Conferences 4
(Date:8/4/2015)... , ... August 04, 2015 , ... The results of ... treat Retinitis pigmentosa, a rare eye disease that progressively causes blindness, were published on ... Ophthalmology. According to the results of the trial, the implant, more commonly known as ...
(Date:8/4/2015)... ... August 04, 2015 , ... More than 700 years ... their wedding vows on Friday, July 24th. Chaplains Shawn Kafader and Richard Oas ... other. Following the ceremony was a reception, with music by the Moonlight Serenade ...
(Date:8/4/2015)... ... 2015 , ... The Law Offices of Ben C. Martin , based ... Inferior Vena Cava Filters (“IVC Filters”). , As lead IVC filter lawyer for the ... clients under In re Cook Medical, Inc., IVC Filters Marketing, Sales Practices and Products ...
(Date:8/4/2015)... ... August 04, 2015 , ... Continuing Education Company ... of an interaction simulation session entitled "NOACS: What the Evidence Shows in Managing ... Learning Institute Inc. and EDUmotion US LLC. , This special activity was recently ...
(Date:8/4/2015)... ... , ... Mr Didier Cauchois, CIO of information systems at ... Mr Cauchois attributes the success to the dedication from the team at COL, ... offered by Winscribe's platform. , "We have already begun to see the ...
Breaking Medicine News(10 mins):Health News:“Bionic Eye” Implant for the Blind Proved Safe and Effective at the End of a Three Year Clinical Trial 2Health News:Couples Renew Vows at Friendship Village of Schaumburg 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 2Health News:Law Offices of Ben C. Martin in Dallas Files New IVC Filter Complications Lawsuits and Pursues Settlements 3Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 2Health News:Innovative Medical Interactive Simulation Session to be presented at upcoming Continuing Education Company Education (CME) Conferences. 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 2Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 3Health News:The Oscar Lambret Center (France) Completes First Stage Of Winscribe Text Rollout 4
... to a small-scale, in-office, observational study, psychiatrists and ... of pediatric ADHD and psychiatric comorbidities, particularly regarding ... which utilized accepted sociolinguistic methodologies to evaluate the ... presented recently at the 20th annual U.S. Psychiatric ...
... symptoms at least once a week, survey shows , , THURSDAY, ... how well asthma patients in the United States think they ... their daily lives, according to a survey released Thursday by ... of the survey respondents said they have their asthma symptoms ...
... that as HIV treatment improved and as HIV-related public ... disease and seek care, that HIV-infected patients would seek ... are actually sicker when they begin therapy. The study ... Infectious Diseases, currently available online. , The study, carried ...
... 25 Cash Technologies, Inc.,(Amex: TQ ... Claim-Remedi,Services, Inc. has entered into a Services ... to incorporate Claim-Remedi,s products into,TriCap,s ARxChange(TM) debt ... centralized on-line marketplace for the disposition of,healthcare ...
... Developer of Zone Sonography(TM) ... ... Systems,a developer of premium ultrasound systems and proprietary Zone,Sonography(TM) technology, announced ... financial officer (CFO). Marcotte has,more than 20 years of finance and ...
... DENVER, Oct. 25 Medical Simulation Corporation (MSC),announces ... Health,System to provide simulation training and education services ... the system,s,flagship facility, the Hospital of the University ... Report as one of the top 18 hospitals ...
Cached Medicine News:Health News:Psychiatrists, parents significantly differ in ADHD, psychiatric comorbidities perceptions 2Health News:Most Asthmatics Don't Have Illness Under Control 2Health News:Most Asthmatics Don't Have Illness Under Control 3Health News:HIV patients sicker when seeking care than in the past 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With TriCap Health Group 2Health News:Cash Technologies Subsidiary Signs Services and Licensing Agreement With TriCap Health Group 3Health News:ZONARE Names Marcotte Chief Financial Officer 2Health News:Medical Simulation Corporation Announces Partnership With University of Pennsylvania Health System 2
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
For temporary cardiac pacing after open heart surgery. The zig-zag portion of the heartwire is embedded into the desired area of the myocardium (epicardially)....
Medicine Products: